Suppr超能文献

同种异体 CD4+ T 细胞转移可挽救抗 PD-L1 耐药肿瘤中的 CD8+ T 细胞,从而导致肿瘤清除。

Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.

机构信息

Department of Pathology, The University of Chicago, Chicago, Illinois.

Department of Health Studies, The University of Chicago, Chicago, Illinois.

出版信息

Cancer Immunol Res. 2017 Feb;5(2):127-136. doi: 10.1158/2326-6066.CIR-16-0293. Epub 2017 Jan 11.

Abstract

Adoptively transferred CD8 T cells can stabilize the size of solid tumors over long periods of time by exclusively recognizing antigen cross-presented on tumor stroma. However, these tumors eventually escape T-cell-mediated growth control. The aim of this study was to eradicate such persistent cancers. In our model, the SIYRYYGL antigen is expressed by cancer cells that lack the MHC-I molecule K needed for direct presentation, but the antigen is picked up and cross-presented by tumor stroma. A single injection of antigen-specific 2C CD8 T cells caused long-term inhibition of tumor growth, but without further intervention, tumors started to progress after approximately 3 months. Escape was associated with reduced numbers of circulating 2C cells. Tumor-infiltrating 2C cells produced significantly less TNFα and expressed more of the "exhaustion" markers PD-1 and Tim-3 than T cells from lymphoid organs. High-dose local ionizing radiation, depletion of myeloid-derived suppressor cells, infusions of additional 2C cells, and antibodies blocking PD-L1 did not prevent tumor escape. In contrast, adoptive transfer of allogeneic CD4 T cells restored the numbers of circulating Ag-specific CD8 T cells and their intratumoral function, resulting in tumor eradication. These CD4 T cells had no antitumor effects in the absence of CD8 T cells and recognized the alloantigen cross-presented on tumor stroma. CD4 T cells might also be effective in cancer patients when PD-1/PD-L1 blockade does not rescue intratumoral CD8 T-cell function and tumors persist. Cancer Immunol Res; 5(2); 127-36. ©2017 AACR.

摘要

过继转移的 CD8 T 细胞通过专门识别肿瘤基质中呈递的抗原,可在很长一段时间内稳定实体瘤的大小。然而,这些肿瘤最终会逃脱 T 细胞介导的生长控制。本研究旨在根除此类持续性癌症。在我们的模型中,SIYRYYGL 抗原由缺乏 MHC-I 分子 K 的癌细胞表达,该分子 K 是直接呈递所必需的,但该抗原被肿瘤基质摄取和交叉呈递。单次注射抗原特异性 2C CD8 T 细胞可长期抑制肿瘤生长,但如果没有进一步干预,肿瘤在大约 3 个月后开始进展。逃逸与循环 2C 细胞数量减少有关。肿瘤浸润的 2C 细胞产生的 TNFα 明显减少,并且表达的“耗竭”标志物 PD-1 和 Tim-3 比来自淋巴器官的 T 细胞更多。高剂量局部电离辐射、髓系来源的抑制细胞耗竭、额外 2C 细胞输注以及阻断 PD-L1 的抗体均不能预防肿瘤逃逸。相比之下,同种异体 CD4 T 细胞的过继转移可恢复循环 Ag 特异性 CD8 T 细胞的数量及其肿瘤内功能,从而导致肿瘤消除。这些 CD4 T 细胞在没有 CD8 T 细胞的情况下没有抗肿瘤作用,并且识别肿瘤基质中呈递的同种异体抗原。当 PD-1/PD-L1 阻断不能挽救肿瘤内 CD8 T 细胞功能且肿瘤持续存在时,CD4 T 细胞在癌症患者中也可能有效。Cancer Immunol Res; 5(2); 127-36. ©2017 AACR.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45dd/5354300/5ecf63a19861/nihms843516f1.jpg

相似文献

2
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.B7-H3 负向调节 CTL 介导的肿瘤免疫。
Clin Cancer Res. 2018 Jun 1;24(11):2653-2664. doi: 10.1158/1078-0432.CCR-17-2852. Epub 2018 Mar 12.

引用本文的文献

4
The role of CD4 T cells in rejection of solid tumors.CD4 T细胞在实体瘤排斥反应中的作用。
Curr Opin Immunol. 2022 Feb;74:18-24. doi: 10.1016/j.coi.2021.09.005. Epub 2021 Oct 4.
7
Epidemiology and biology of relapse after stem cell transplantation.干细胞移植后复发的流行病学与生物学特性
Bone Marrow Transplant. 2018 Nov;53(11):1379-1389. doi: 10.1038/s41409-018-0171-z. Epub 2018 Apr 18.

本文引用的文献

1
The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process.癌症的生态与进化:超微进化过程
Annu Rev Genet. 2016 Nov 23;50:347-369. doi: 10.1146/annurev-genet-112414-054842. Epub 2016 Sep 28.
5
Characteristics of Exceptional or Super Responders to Cancer Drugs.癌症药物的卓越或超强应答者的特征。
Mayo Clin Proc. 2015 Dec;90(12):1639-49. doi: 10.1016/j.mayocp.2015.08.017. Epub 2015 Nov 3.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验